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ABSTRACT 
Spinal muscular atrophy (SMA) is a severe autosomal recessive motor neuron disease caused by loss 
of SMN1, which encodes a protein essential for motor neuron survival. SMA patients have one or 
more copies of an alternate SMN gene, SMN2, which is nearly identical to SMN1. SMN2 differs at a 
single nucleotide from SMN1 which results in the skipping of exon 7 in the mRNA and produces an 
unstable protein (SMNΔ7). Therapeutic approaches that have been undertaken include i) 
replacement of SMN1 by gene delivery mediated by adeno-associated virus serotype 9 (AAV9) 
(Zolgensma), ii) correction of the aberrant SMN2 splicing using an antisense oligonucleotide (ASO) 
or small molecule (nusinersin, risdiplam), and iii) increased expression of SMN2 mediated by histone 
deacetylase (HDAC) inhibitors. Two of these three approaches have given rise to successful 
treatments for SMA, but they are very expensive, and their long-term safety is not well known. In 
addition, the ability of ASOs and viral vectors to reach their targets in the CNS with peripheral 
administration is limited. Small molecules may cross the brain blood barrier when orally delivered 
and can be discontinued if needed to mitigate adverse effects. This Editorial highlights the current 
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study by Pagliarni et al. in which they used combined treatment of cell models of SMA with an ASO 
and an orally delivered HDAC inhibitor (panobinostat) to overcome the limitations of a single 
therapeutic approach.  Panobinostat enhanced the expression of SMN2, increasing the amount of 
SMN2 mRNA available for splicing correction mediated by the ASO. In addition, panobinostat 
increased exon 7 retention in the SMN2 mRNA. This combinatorial treatment might allow lower or 
less frequent ASO doses, reducing the need for repeated intrathecal administration. The combined 
effects of panobinostat and nusinersen can now be tested in SMA animal models to determine 
whether this approach will be translatable to patients.   
 
ABBREVIATIONS: AAV9= adeno-associated virus serotype 9; ASO = antisense oligonucleotide; EMA 
= European Medicine Agency; FDA = Food and Drug Administration; HDAC = histone deacetylase; 
SMA = Spinal muscular atrophy; SMN1= survival motor neuron 1; SMN2= survival motor neuron 2; 
SMN7 = survival motor neuron 2 lacking exon 7 
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EDITORIAL 
Spinal muscular atrophy (SMA) is a severe autosomal recessive motor neuron disease characterized 
by muscle weakness and atrophy, with a variable loss of motor function. The deficit is a direct 
consequence of the degeneration of motor neurons in the anterior horns of the spinal cord. These 
motor neurons directly connect the nervous system with skeletal muscle fibers to control voluntary 
movements. Different SMA forms have been described (types I, II and III), which are clinically 
characterized by age of onset and severity. Most SMA cases appear as the severe form in the first 
few months of age, while in other cases the disease shows later onset of symptoms, after the first 
year of age. The third form of SMA occurs in children and adolescents and is characterized by a less 
severe deficit with a slow rate of progression. In addition to these, other SMA forms are 
embryonically lethal (type 0) or occur with a mild phenotype in early adulthood (type IV). 
Despite the differing manifestations, all SMA forms are due to homozygous deletions and other 
mutations in the survival motor neuron 1 (SMN1) gene, which encodes a protein essential to 
maintain motor neuron viable, thus preventing their death (Lefebvre et al. 1995). The differences in 
SMA phenotype from type 0 to type IV are due to variable copies of a second SMN gene (SMN2), 
which is highly homologous to SMN1 (figure 1). SMN2 has five nucleotide differences compared to 
SMN1, one of which, a substitution of a cytidine with a thymine (C  T) in exon 7 (Monani et al. 
1999; Lorson et al. 1999) causes the SMN2 primary transcript to undergo alternative splicing which 
causes the loss of exon 7 in the mature mRNA. The encoded protein (SMN7) is shorter and 
unstable, but small amounts of normally spiced mRNA, and consequently full-length active protein 
(FL-SMN), are also produced from the SMN2 gene. The severity of SMA is thus due to the 
combination of the SMN2 copy number and its ability to produce an active SMN protein, which 
partially rescues the defect associated with loss of SMN1 in patients.  
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Therapeutic approaches for SMA can thus be based on a) restoration of normal SMN1, b) 
induction of a proper SMN2 splicing to allow exon 7 retention in mature mRNA, or c) transcriptional 
or translational stimulation of the SMN2 gene product (figure 1). Over the past 20 years, these 
experimental and clinical approaches have resulted in precise therapeutic strategies that are now 
approved by regulatory agencies worldwide. 
Restoration of normal SMN1 levels in affected cells has been achieved using adeno-associated 
virus serotype 9 (AAV9) vector to deliver the cDNA encoding SMN1 (onasemnogene abeparvovec-
xioi, Zolgensma®) (Mendell et al. 2017). The AAV9 vector is able to cross the brain-blood barrier, 
and this strategy is based on a single dose, administered intravenously, of the viral vector expressing 
SMN1. Clinical trials have shown a marked improvement of the clinical signs in the SMA-affected 
infants, as measured with the CHOP INTEND (Children’s Hospital of Philadelphia Infant Test of 
Neuromuscular Disorders) scale of motor function. The motor functions were significantly better 
than expected on the basis of the natural history of children affected by the same type of SMA, and 
were maintained and improved during the follow-up period. 
Zolgensma is now approved by the Food and Drug Administration (FDA), European Medicine Agency 
(EMA), and other regulatory agencies for intravenous administration in early onset SMA. In addition, 
intrathecal administration in older patients has been under investigation in a clinical trial (STRONG, 
NCT03381729). 
Correction of SMN2 splicing is now possible with an antisense oligonucleotide (ASO) designed to 
block the alternative splicing that deletes exon 7 from the transcript. The ASO blocks the intronic 
splicing silencer element located in intron 7, and directs the splicing to exon 7 instead of exon 8 
(Hua et al. 2010). The ASO binds specifically to this site, sterically inhibiting the binding of the splicing 
factor and thus repairing the mRNA of SMN2 and allowing the synthesis of a fully functional SMN2 
protein. 
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Phase II and III clinical trials performed in SMA-type I, II and III-affected showed impressive 
efficacy (Finkel et al. 2017). Patients who were administered the ASO had improvement in clinical 
signs, with increased time to death or need for permanent ventilatory support when compared to 
sham-control group. These results were confirmed in other trials, which were terminated early to 
allow treatment for all study participants. The ASO, developed by Ionis and known as nusinersen, 
was further developed by Biogen with the commercial name of Spinraza®, and readily approved by 
the FDA, EMA, and other regulatory agencies. A disadvantage of nusinersen compared to 
Zolgensma, is that the ASO must be administered intrathecally repeatedly, three times per year 
after the first year of treatment. A comparison between the viral mediated delivery of SMN1 and 
the spicing correction approach mediated by ASO is described in recent commentaries (Ridler 2018; 
Whittaker & Michell-Robinson 2018).  
A similar approach based on the restoration of a proper splicing of the SMN2 transcript has been 
pursued with the small molecules risdiplam (from Roche, currently under review for approval by the 
FDA and EMA) and branaplam (from Novartis), which have the advantage of being orally 
bioavailable and brain-penetrant. Both compounds ameliorate motor function in mouse studies, 
and in clinical trials risdiplam may be as effective as intrathecal nusinersen. 
Other attempts to enhance and restore the expression of a functional SMN protein have been 
based on the use of histone deacetylase (HDAC) inhibitors, including sodium butyrate, valproic acid, 
trichostatin, and panobinostat (Chang et al. 2001; Sumner et al. 2003; Avila et al. 2007; Garbes et 
al. 2009). Of these drugs, only valproic acid has been tested in SMA patients, and without positive 
results (Swoboda et al. 2009).  
The new therapeutic approaches often incur a high cost that may limit access for many patients 
worldwide. In addition, the long-term tolerability and safety are not yet fully known. Moreover, it is 
unknown at present how many motor neurons are targeted by an ASO or a viral vector, and how 
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long these agents will exert their action in each cell. Neither approach can yet be considered a 
complete cure for SMA (Finkel et al. 2017; Mercuri et al. 2018).  
A small molecule that can be delivered to all target cells may help to sustain or potentiate the 
action of a genetic intervention for SMA. Small molecules may be developed to cross the brain blood 
barrier and to be administered orally to maintain therapeutic levels and also readily discontinued in 
case of adverse effects. Small molecule pharmacokinetics can be optimized for penetration into 
skeletal muscle, which is may be affected by SMN deficiency in SMA, reaching each muscle fiber, 
which is difficult go attain with viral vectors and ASOs.  
To circumvent potential limitations of the therapeutic approaches now in clinical use, in Pagliarini 
et al. (Pagliarini et al. 2019), in a recent study reported in The Journal of Neurochemistry, have 
assessed combinatorial treatment for SMA, using an ASO (ASO_ISSN1, to mimic the effects of 
nusinersen) and panobinostat, a small molecule that can be orally administered, crosses the blood-
brain barrier, and is active in the nanomolar range to increase the SMN protein levels in SMA 
models. Of note, panobinostat has FDA approval for multiple myeloma and is generally well 
tolerated in patients. 
Pagliarini et al. used fibroblasts from type I SMA patients and murine neural stem cells (NSCs) 
isolated from SMA mice and showed that panobinostat has selective effects on SMN2 exon 7 
splicing. They found that panobinostat is more active than other known HDAC inhibitors in restoring 
the splicing of exon 7 of the SMN2 transcripts, acting at doses of 25 nM. These concentrations may 
be achievable in the brain, as demonstrated in a clinical trial for glioma, and this may be an 
advantage compared to other treatments (NCT00848523). It is possible that the dose needed for 
this effect may be lower than is used for treatment of multiple myeloma.  
The authors also tested the potential additive effects of panobinostat and the ASO_ISSN1, using 
as readout the splicing of exon 7 of SMN2 transcript (Pagliarini et al. 2019). They demonstrated that 
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in the combinatorial treatment panobinostat increases the effects of the ASO on exon 7 retention 
in the SMN2. It is still unclear how this additive (or synergistic) effect is obtained in cells, but the 
authors found that panobinostat also enhances the expression of the SMN2 gene by inducing 
histone acetylation and consequently chromatin relaxation at the SMN2 locus. This increases the 
amount of the template SMN2 transcript that is available for splicing repair by the ASO. One relevant 
aspect in the study, is that the ASO_ISSN1 was given at an otherwise subtherapeutic dose (20 nM), 
suggesting that the combinatorial treatment might allow patients to be treated with a splice-
switching ASO at a lower dose or the same dose with a longer duration of effect, thus reducing the 
need for repeated intrathecal administration (Pagliarini et al. 2019). It is now necessary to test the 
combinatorial effects of panobinostat and nusinersen in preclinical animal models of SMA, before 
drawing conclusions about whether this approach will be translatable to patients.   
Since nusinersen does not cross the brain blood barrier, at least three intrathecal injections per 
year are required to obtain the full pharmacological effects in patients, and this may need to be 
maintained for the entire life of the patient. If the combinatorial treatment is proven to be effective 
in preclinical and clinical studies, then this may allow less frequent invasive therapeutic intervention 
in SMA patients. Combinatorial treatment may also help to reduce the high cost of the treatment 
and perhaps avoid side effects of long term ASO treatment.  
The same strategy of combinatorial treatment could also be evaluated in SMA patients treated 
with Zolgensma. Adjunctive HDAC treatment might help to sustain the efficacy of gene replacement 
or extend the benefit to motor neurons that have not been transfected with the viral vector. This 
combinatorial approach could also be assessed for small molecules that restore SMN2 exon 7 
splicing, such as risdiplam, where clinical trials are showing benefit in SMA patients. 
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This manuscript is dedicated to the memory of our friend and colleague Giorgio Battaglia, who spent 
his scientific career in studying Spinal muscular atrophy. 
 
Figure legend:  
 
Figure. Targets for spinal muscular atrophy (SMA) treatment. SMA is caused by loss of functional 
SMN1. SMA patients have one or more copies of SMN2, which is nearly identical to SMN1, but has 
a single nucleotide difference that causes skipping of exon 7 in the mRNA. The mRNA lacking exon 
7 (SMNΔ7) is unstable and relatively non-functional. Therapeutic approaches include replacing 
SMN1 by gene delivery (Zolgensma), correcting the splicing of the SMN2 mRNA (nusinersin, 
risdiplam), and increasing expression of SMN2 (histone deacetylase inhibitors). Combinatorial 
treatments based on enhanced SMN2 expression and splicing correction have been found promising 
in cell models of SMA. 
 
